Tonix Pharmaceuticals BIO 2024 Corporate Presentation

Tonix Pharmaceuticals Holding Corp. presents its development pipeline focused on Tonmya (TNX-102 SL), a candidate for fibromyalgia management, at BIO International 2024. The company develops therapeutics for pain, neurologic, psychiatric, and addiction conditions through its central nervous system portfolio. Tonix is pursuing a New Drug Application filing with the FDA for Tonmya's approval.